Our pipeline diagnostics

Detecting disease using protein biomarkers and proprietary algorithms

Nonagen Bioscience’s pipeline diagnostics are being developed as Multianalyte Assays with Algorithmic Analyses (MAAAs), which look at the proprietary differential expression of biomarkers (analytes) in specific types of cancer and use novel algorithms to score a patient’s probability of harboring cancer. The assays are being developed as rule in tests with a very high sensitivity and equally high negative predictive value. 

Research, development, and commercialization timeline

Nonagen Bioscience is developing several diagnostic tests to address unmet needs in bladder, breast, and prostate cancers. These diagnostics are being designed to complement the current standards of care with the goal of serving as additional tools for early detection, treatment monitoring, and prediction.

Oncuria® is Nonagen Bioscience’s lead diagnostic. It is a first-of-its-kind multiplex, protein-based urine test for the early and accurate diagnosis of bladder cancer. Oncuria addresses an unmet clinical need for a noninvasive diagnostic tool. It also presents significant opportunities to improve patient outcomes and reduce healthcare spending. 

Pipeline snapshot

Oncuria clinical trials

The multiplex Oncuria test was developed to address the highly recurrent nature of bladder cancer. The clinical studies outlined in the chart below are testing the performance and clinical utility of Oncuria. 

A game-changing test for bladder cancer

Discover why Oncuria has earned Breakthrough Device Designation status from the US Food and Drug Administration (FDA).